NCT04577781

A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate

A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of GLPG3970, Administered Orally for 6 Weeks in Adult Subjects With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 28 (actual)
• Sponsor: Galapagos NV · Industry
• Sex: All
• Age: 18 Years – 64 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this study was to evaluate the effect of GLPG3970 compared to placebo on the signs and symptoms of Rheumatoid Arthritis (RA) in participants with moderately to severely active RA and an inadequate response to methotrexate (MTX).

Conditions

• Rheumatoid Arthritis

Interventions

Type	Name	Description
DRUG	GLPG3970	GLPG3970 powder and solvent for oral solution to be reconstituted prior to use.
DRUG	Placebo	Placebo powder and solvent for oral solution to be reconstituted prior to use.

Timeline

• Start date: 2020-10-12
• Primary completion: 2021-03-26
• Completion: 2021-04-07
• First posted: 2020-10-08
• Last updated: 2022-07-18
• Results posted: 2022-07-18

Locations

9 sites across 4 countries: Bulgaria, Georgia, Poland, Ukraine